KABI PHARMACIA’s DIPENTUM CONSENT DECREE REQUIRES FDA-APPROVED TRAINING PROGRAM FOR SALES REPS; JULY 30 ORDER IS FDA’s FIRST "SIGNIFICANT" DETAILING CASE

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".